Some chemicals act like fake hormones, tricking the body and causing reproductive or developmental issues. Instead of relying on old-school animal testing, this work uses high-tech cell cultures and computer models to spot these triggers. It's like upgrading from a rough sketch to a high-definition 3D map of how toxins affect human growth.
Companies face high costs and ethical hurdles using animal testing to prove their chemicals are safe. There is a lack of accepted, non-animal alternatives that regulators trust to identify endocrine disruptors.
The project is building a roadmap for EDC identification, including testis- and ovary-specific in vitro assays and quantitative Adverse Outcome Pathways.
If you are a skincare manufacturer dealing with strict EU chemical safety laws — this project developed New Approach Methodologies (NAMs) that provide faster, non-animal ways to prove your ingredients don't disrupt hormones.
If you are a drug developer dealing with toxicity screening for new compounds — this project developed transcriptomics and biomarker identification tools that predict adverse effects on sexual development more accurately than traditional tests.
If you are a chemical producer dealing with the risk of products being banned as endocrine disruptors — this project developed a roadmap for identification using Adverse Outcome Pathways to provide evidence-based safety data.
Based on available project data, no specific pricing or commercial cost for the methodologies is provided, as the project is EU-funded research.
The project is currently developing in vitro assays and brain models. Based on available project data, these are intended to support human-relevant toxicity assessments, but industrial scale-up details are not specified.
Based on available project data, there is no mention of specific licensing terms or patent filings; the focus is on informing EU regulations and policies.
The project maps EU regulatory landscapes and aims to provide a roadmap for the use of New Approach Methodologies in the identification of endocrine disruptors.
The project period runs from 2024-01-01 to 2028-12-31, meaning the final validated tools and roadmap will be available by the end of 2028.
The consortium is heavily academic, consisting of 12 partners from 8 countries, with 6 universities and 4 research institutions. There are 0 industry partners and 0 SMEs, indicating that the current output is focused on scientific validation and regulatory influence rather than immediate commercial productization.
Contact Danmarks Tekniske Universitet regarding the NAMs roadmap.
Contact us to find a partner for implementing these NAMs in your safety testing pipeline.
